source
- FDA reviewers doubt Replimune’s melanoma therapy as shares tumble 40%Replimune's shares fell nearly 40% after FDA reviewers released briefing documents expressing skepticism about its experimental melanoma drug RP1. RP1 has been rejected twice before; the company l…
- Biogen's $5.6B Apellis Purchase Boosts Q2 Revenue Above ForecastsBiogen began reporting revenue from its $5.6 billion acquisition of Apellis in the second quarter, pushing earnings above analysts' consensus estimates. CEO Chris Viehbacher said the company will…